Market Overview:
The global selective serotonin reuptake inhibitors (SSRIs) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The SSRI class of drugs are used in the treatment of various mental conditions, such as depression, anxiety and panic disorder, and other mental conditions. These drugs work by increasing the levels of serotonin in the brain. North America dominates the global SSRI market due to high prevalence of mental disorders and early adoption of novel therapies. However, Asia Pacific is expected to grow at a highest CAGR during the forecast period owing to rising awareness about mental health disorders and increasing healthcare expenditure in this region. Based on type, citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac), paroxetine (Paxil/Pexeva), sertraline (Zoloft) and vilazodone (Viibryd) are some major types available in this market.
 Industry Outlook.svg)
Product Definition:
Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressants that work by restoring the balance of serotonin in the brain. Serotonin is a neurotransmitter that helps regulate mood, anxiety, and sleep. SSRIs are important because they are one of the most effective classes of antidepressants available, and they have relatively few side effects.
Citalopram (Celexa):
SSRIs are a class of antidepressants drugs. They inhibit the reabsorption of serotonin through certain nerve cells situated in the brain. This leads to an increase in the amount of serotonin available for uptake by nerve cells, which results in increased mood stability and reduced anxiety levels.
Escitalopram (Lexapro):
Escitalopram (lexapro) is an SSRI drug developed by Cipla, a Indian based company. It was launched in May 2006 in the U.S and later received FDA approval in October of that year. Lexapro is the generic name for Escitalopram and its brand names include Calan, Vraylar, Rxsulid and Nerventra among others.
Application Insights:
On the basis of application, the global selective serotonin reuptake inhibitors (SSRIs) market is segmented into depression, anxiety and panic disorder, other mental conditions. The other mental conditions segment held the largest share in 2017 due to high prevalence of anxiety disorders such as social phobia and OCD. According to a study published by WHO in 2018, around one in five people suffer from some form of anxiety disorder each year.
The depression segment is also expected to grow at a significant rate during the forecast period owing to increasing cases of clinical depression across all age groups and genders. As per Mental Health America (MHA), around 6%of adults aged 18 years or above suffered from major depressive episode (MDD) in 2015 while 3%of adults aged 18-25 years had MDD that same year. Furthermore, according double edged sword theory proposed by Levy et al.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to witness growth during the forecast period due to rising cases of mental disorders and increasing awareness about their treatment. In addition, presence of a large number of manufacturers in this region is also expected to drive the market for SSRIs in this region.
Asia Pacific is anticipated to be one of the fastest-growing regions over the forecast period owing to an increase in healthcare expenditure and growing patient pool suffering from depression and anxiety disorders coupled with other mental conditions such as bipolar disorder, OCD, schizophrenia etc., which are highly responsiveto SSRI therapy. Moreover, availabilityof generic drugs for some conditions may reduce cost burden on patients resulting into increased demand for medicines like selective serotonin reuptake inhibitors (SSRIs).
Growth Factors:
- Increasing prevalence of depression and anxiety disorders: The major growth driver for the SSRIs market is the increasing prevalence of depression and anxiety disorders. According to the World Health Organization, around 350 million people suffer from depression, making it one of the most common mental disorders in the world. Similarly, anxiety disorders are also very common, with around 264 million people affected worldwide. This growing population is expected to drive demand for SSRIs in coming years.
- Rising awareness about mental health: There is a growing awareness about mental health issues among people across all age groups. This has led to an increase in demand for treatment options such as SSRIs.
- Growing use of antidepressants in children and adolescents: Antidepressants are increasingly being prescribed to children and adolescents owing to rising awareness about their benefits among doctors and parents alike . The use of SSRIs specifically in this population is expected to grow significantly over the next few years .
Scope Of The Report
Report Attributes
Report Details
Report Title
Selective Serotonin Reuptake Inhibitors (SSRIs) Market Research Report
By Type
Citalopram (Celexa), Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine (Paxil, Pexeva), Sertraline (Zoloft), Vilazodone (Viibryd)
By Application
Depression, Anxiety and panic disorder, Other mental conditions
By Companies
Allergan Plc, Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Pfizer Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Report Segments:
The global Selective Serotonin Reuptake Inhibitors (SSRIs) market is segmented on the basis of:
Types
Citalopram (Celexa), Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine (Paxil, Pexeva), Sertraline (Zoloft), Vilazodone (Viibryd)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Depression, Anxiety and panic disorder, Other mental conditions
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan Plc
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- H. Lundbeck AS
- Pfizer Inc.
 Market Overview.svg)
Highlights of The Selective Serotonin Reuptake Inhibitors (SSRIs) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Citalopram (Celexa)
- Escitalopram (Lexapro)
- Fluoxetine (Prozac)
- Paroxetine (Paxil, Pexeva)
- Sertraline (Zoloft)
- Vilazodone (Viibryd)
- By Application:
- Depression
- Anxiety and panic disorder
- Other mental conditions
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Selective Serotonin Reuptake Inhibitors (SSRIs) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Selective serotonin reuptake inhibitors (SSRIs) are a type of antidepressant medication. They work by increasing the amount of serotonin in the brain. This can help to improve mood and reduce anxiety symptoms. SSRIs are often recommended as first-line treatment for major depression, although they may also be used for other conditions such as obsessive compulsive disorder (OCD).
Some of the major players in the selective serotonin reuptake inhibitors (ssris) market are Allergan Plc, Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Pfizer Inc..
The selective serotonin reuptake inhibitors (ssris) market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Selective Serotonin Reuptake Inhibitors (SSRIs) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Selective Serotonin Reuptake Inhibitors (SSRIs) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size & Forecast, 2018-2028
4.5.1 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size and Y-o-Y Growth
4.5.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Absolute $ Opportunity
Chapter 5 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Type
5.2.1 Citalopram (Celexa)
5.2.2 Escitalopram (Lexapro)
5.2.3 Fluoxetine (Prozac)
5.2.4 Paroxetine (Paxil
5.2.5 Pexeva)
5.2.6 Sertraline (Zoloft)
5.2.7 Vilazodone (Viibryd)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Applications
6.2.1 Depression
6.2.2 Anxiety and panic disorder
6.2.3 Other mental conditions
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Analysis and Forecast
9.1 Introduction
9.2 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Type
9.6.1 Citalopram (Celexa)
9.6.2 Escitalopram (Lexapro)
9.6.3 Fluoxetine (Prozac)
9.6.4 Paroxetine (Paxil
9.6.5 Pexeva)
9.6.6 Sertraline (Zoloft)
9.6.7 Vilazodone (Viibryd)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Applications
9.10.1 Depression
9.10.2 Anxiety and panic disorder
9.10.3 Other mental conditions
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Analysis and Forecast
10.1 Introduction
10.2 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Type
10.6.1 Citalopram (Celexa)
10.6.2 Escitalopram (Lexapro)
10.6.3 Fluoxetine (Prozac)
10.6.4 Paroxetine (Paxil
10.6.5 Pexeva)
10.6.6 Sertraline (Zoloft)
10.6.7 Vilazodone (Viibryd)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Applications
10.10.1 Depression
10.10.2 Anxiety and panic disorder
10.10.3 Other mental conditions
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Type
11.6.1 Citalopram (Celexa)
11.6.2 Escitalopram (Lexapro)
11.6.3 Fluoxetine (Prozac)
11.6.4 Paroxetine (Paxil
11.6.5 Pexeva)
11.6.6 Sertraline (Zoloft)
11.6.7 Vilazodone (Viibryd)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Applications
11.10.1 Depression
11.10.2 Anxiety and panic disorder
11.10.3 Other mental conditions
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Analysis and Forecast
12.1 Introduction
12.2 Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Type
12.6.1 Citalopram (Celexa)
12.6.2 Escitalopram (Lexapro)
12.6.3 Fluoxetine (Prozac)
12.6.4 Paroxetine (Paxil
12.6.5 Pexeva)
12.6.6 Sertraline (Zoloft)
12.6.7 Vilazodone (Viibryd)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Applications
12.10.1 Depression
12.10.2 Anxiety and panic disorder
12.10.3 Other mental conditions
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Selective Serotonin Reuptake Inhibitors (SSRIs) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Type
13.6.1 Citalopram (Celexa)
13.6.2 Escitalopram (Lexapro)
13.6.3 Fluoxetine (Prozac)
13.6.4 Paroxetine (Paxil
13.6.5 Pexeva)
13.6.6 Sertraline (Zoloft)
13.6.7 Vilazodone (Viibryd)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Forecast by Applications
13.10.1 Depression
13.10.2 Anxiety and panic disorder
13.10.3 Other mental conditions
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Competitive Dashboard
14.2 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan Plc
14.3.2 Eli Lilly and Co.
14.3.3 GlaxoSmithKline Plc
14.3.4 H. Lundbeck AS
14.3.5 Pfizer Inc.
